- Home
- FDBC vs PROK Comparison
FDBC vs PROK Comparison
Compare FDBC & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FDBC
- PROK
- Stock Information
- Founded
- FDBC 1902
- PROK 2015
- Country
- FDBC United States
- PROK United States
- Employees
- FDBC N/A
- PROK 163
- Industry
- FDBC Major Banks
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FDBC Finance
- PROK Health Care
- Exchange
- FDBC Nasdaq
- PROK Nasdaq
- Market Cap
- FDBC 253.4M
- PROK 212.4M
- IPO Year
- FDBC N/A
- PROK N/A
- Fundamental
- Price
- FDBC $43.51
- PROK $1.66
- Analyst Decision
- FDBC
- PROK Buy
- Analyst Count
- FDBC 0
- PROK 5
- Target Price
- FDBC N/A
- PROK $4.50
- AVG Volume (30 Days)
- FDBC 9.0K
- PROK 566.3K
- Earning Date
- FDBC 01-27-2025
- PROK 11-12-2024
- Dividend Yield
- FDBC 3.68%
- PROK N/A
- EPS Growth
- FDBC N/A
- PROK N/A
- EPS
- FDBC 2.68
- PROK N/A
- Revenue
- FDBC $71,243,000.00
- PROK N/A
- Revenue This Year
- FDBC N/A
- PROK N/A
- Revenue Next Year
- FDBC N/A
- PROK N/A
- P/E Ratio
- FDBC $16.25
- PROK N/A
- Revenue Growth
- FDBC N/A
- PROK N/A
- 52 Week Low
- FDBC $41.00
- PROK $1.18
- 52 Week High
- FDBC $61.21
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- FDBC 33.38
- PROK 46.29
- Support Level
- FDBC $41.00
- PROK $1.50
- Resistance Level
- FDBC $45.27
- PROK $1.90
- Average True Range (ATR)
- FDBC 1.29
- PROK 0.15
- MACD
- FDBC -0.20
- PROK -0.01
- Stochastic Oscillator
- FDBC 28.52
- PROK 45.45
About FDBC Fidelity D & D Bancorp Inc.
Fidelity D & D Bancorp Inc is a bank holding company. Through its wholly-owned state-chartered commercial bank subsidiary, The Fidelity Deposit and Discount Bank (the Bank), it offers a full range of traditional banking services. The Bank has a personal and corporate trust department and also provides alternative financial and insurance products with asset management services. Its primary market areas are Lackawanna, Luzerne and Northampton Counties, Pennsylvania. The company's primary deposit products are demand deposits and interest-bearing time, money market and savings accounts. It offers a full array of loan products to meet the needs of retail and commercial customers.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.